SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Kakkar A. K.)
 

Search: WFRF:(Kakkar A. K.) > Major joint replace...

  • Dahl, O. E. (author)

Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • 2008

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/107031
  • https://gup.ub.gu.se/publication/107031URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • AIM: Development of antithrombotic compounds has traditionally been performed in patients undergoing total hip and knee replacement surgery. A high number of asymptomatic deep-vein thromboses are radiologically detectable, and bleeding and other adverse events (AE) are easy to observe. However, standardization of study procedures and endpoints in early proof-of-concept studies and late pure clinical endpoint studies has been lacking. This has made comparison between studies difficult, economic analyses speculative and potential benefits of applying the drug regimen in non-selected patients uncertain. In this paper, the International Surgical Thrombosis Forum proposes a strategy for the clinical investigation of new pharmacological agents for the prophylaxis of postoperative thrombotic events. METHODS: First, dose titration safety studies of short duration, in highly selected patients using objective venographic endpoints are recommended. Bleeding should be divided into the quantified volume of surgical bleeding and other adjudicated clinical bleeding events. The number of AE should be described for each dose step and classified according to International Coding of Diagnoses (ICD). Second, a dose confirmatory study of moderate exposure period and sufficient follow-up time is recommended. The exclusion criteria should be restricted to contraindications of the compared drugs and technical procedure. RESULTS: The efficacy, bleeding and AE should be similar to those used in dose-titration studies. In addition, the failure rate of the drug to exert its effect and the net clinical benefit should be calculated. CONCLUSION: Finally, trials with simple clinical endpoints and long follow-up should be conducted to evaluate the potential benefits of the drug-regimen in non-selected populations.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Borris, L. C. (author)
  • Bergqvist, D. (author)
  • Schnack Rasmussen, M. (author)
  • Eriksson, Bengt I.,1946Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xerben (author)
  • Kakkar, A. K. (author)
  • Colwell, C. W. (author)
  • Caprini, J. A. (author)
  • Fletcher, J. (author)
  • Friedman, R. J. (author)
  • Lassen, M. R. (author)
  • Frostick, S. P. (author)
  • Sakon, M. (author)
  • Kwong, L. M. (author)
  • Kakkar, V. V. (author)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper (creator_code:org_t)

Related titles

  • In:International angiology27:1, s. 60-70392-9590

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view